• 대한물리치료과학회지
• /
• 제8권2호
• /
• pp.977-987
• /
• 2001

The purpose of this study was to examine the effects of sensory integration therapy (SIT) on sensory' motor development and adaptive behavior of cerebral palsy children. The design of this study was quasi experiments with a non-equivalent pre- and post-test control design. Subjects of the study were arbitrarily chosen based on predetermined selection criteria among the cerebral palsy children who were treated as out-patients at two rehabilitation hospitals one in Seoul, and the other in Kyunggi-do. The study was conducted between early April and late July in 2000. Fifteen children were in the experimental group and eleven in the control group. The allocation was done based on ease of experimental treatment. A five-step SIT program was devised from a combination of SIT programs suggested by Ayres(1985) and Finks(1989), and an author-designed SIT program for cerebral palsy children. The experimental group was subjected to 20 to 30 minutes of SIT per session. two sessions a week for ten -week period. The effects of SIT were measured with respect to 9 sub-areas that can be administered to cerebral palsy children out of a total of 17 sub-areas in the Southern California Sensory Integration Test (SCSIT) developed by Ayres (1980). In addition. the scale developed by Russell (1993) for Gross Motor Function Measure (GMFM). and Perception Motor Development Test developed by 中司利一 et al.(1987) were also applied. Adaptive behavior was analyzed using guidelines in two unpublished documents - School-Age Checklist for Occupational Therapy by the Wakefield Occupational Therapy Associates, and the OTA-Watertown Clinical Assessment by the Watertown Occupational Therapy Associates-, and an author-developed Adaptive Behavior Checklist. Collected data were statistically analyzed by SPSS PC for chi square test, Mann-Whitney test, Wilcoxon signed rank test, and paired t-test. The results were as follows: 1. In sensory development, the experimental group exhibited a score increase compared to the control group, but the difference was not statistically significant, Although the experimental group showed improvements in all. 9 sub-areas compared to the control group, only right-left discrimination exhibited statistically significant change. 2. In gross motor development, the experimental group showed improvements in score compared to the control group, but it was not statistically significant. In fine motor development, the experimental group exhibited statistically significant improvements compared to the control group. In sub-area analysis, figure synthesis showed positive change. 3. In adaptive behavior development, post-experimental adaptive behavior scores were higher compared to pre-experimental scores with statistical significance. Furthermore, sub-areas emotional behavior, perception behavior, gross-fine motor function, oral-respiration function, motor behavior, motor planning, and adaptive response exhibited higher scores after SIT. In conclusion SIT was found to be partially effective in sensory and fine motor development, effective in all adaptive behavior areas, and not effective in gross motor development. Thus, this study has shown that SIT is an effective intervention for sensory development, fine motor development, and adaptive behavior for cerebral palsy children. But, for the effectiveness of SIT on gross motor development, further studies employing longer-time experiments are recommended.

• 대한한의학회지
• /
• 제29권2호
• /
• pp.165-181
• /
• 2008

Objectives: This study was conducted to help clinical studies for treating the common cold with Oriental medicine. We inspected tendencies of clinical studies of the common cold in western medicine and analyzed the assessing instruments for it by scrutinizing PubMed publications for the last five years. Materials and Methods: We inspected 32 theses and scrutinized their objectives, periods, participants, materials and methods, the instrument of assessment for the studies, and validity, reliability, criteria and symptom score for questionnaires, results and JADAD score. Results: 1. The median for total period of study was 7 months, the median for days of treatment was 7.5, and most studies were carried out during the winter/spring period, because of the enhanced risk of cold infections. 2. The studies focused on unorthodox medicines or new drug products, such as antipyretic analgesics (e.g. paracetamol), decongestant and bronchodilator (e.g. ephedrine), echinacea, antioxidants (e.g. zinc), probiotic bacteria and so on. 3. All theses except one had subjectscomposed of cold patients who were infected naturally. The median number of subjects for final analysis was 187. 4. 27 studies used survey as the instrument of assessment. Among these, only one thesis was verified for validity. 5. The mean of JADAD score was 4.41, suggesting most of theses of worth. 7 studies were assessed as ineffective. Conclusion: Recent studies of the common cold are focused on unorthodox medicines or new drug products, and it is necessary to provide an objective instrument for assessing common cold treatments.

• 무역상무연구
• /
• 제69권
• /
• pp.589-616
• /
• 2016

The reviewing of an analysis of the Korea-China FTA due to guidance introduced for the new regulations or exceptional regulations compared to the KORUS, Korea-EU, Korea-ASEAN FTA. Commodity sectors in the Korea-China FTA and the KORUS, Korea-EU, Korea-ASEAN FTA(the majority in the country and trade criteria analysis result) compared and analyzed the results, rules of origin and the customs clearance procedures of origin, preferential tariff rate of origin and the origin preferential specific rules are somewhat difference, but customs and trade facilitation regulations are already quite consistent with the Korea customs system. Relatively important research results were as follows. First, the calculation of the regional value content in KORCHINA FTA is that I'm to use the deduction method can comprehensively reflect a regional value ratio, with respect to the materials acquired originating status as the FTA in the US and EU use the product non it's not to consider the value of the originating materials originating materials can be utilized for intermediate goods. Second, even if a non-treaty country in the middle with the exception of direct transport rules, and acknowledge the country of origin are under customs control, there are provisions for the period are temporarily stored in a non-treaty countries separately, that period goods imported into the non-treaty countries and up to three months from the day. If the situation of the occurrence of force majeure be greater than three months, but has so exceed six months. Third, the materials acquired originating status in the Korea-China FTA not to consider the value of non-originating materials used in its products as the KORUS FTA and Korea-EU FTA, that can be utilized originating materials for intermediate goods. It is expected that higher utilization of rules of origin. Meanwhile, Korea-China FTA has provisions to allow requests for preferential tariff applied on imports Customs declaration of intention to apply pre-condition for a preferential tariff applied to the importer. In other words, if the import customs tariff preference when applying post-intention not to advance is to be noted that any preferential treatment to prevent the later application.

• 한국터널지하공간학회 논문집
• /
• 제19권3호
• /
• pp.533-549
• /
• 2017

본 연구에서는 지하 콘크리트 구조물 내로 누수된 지하수를 유도하여 배수하는 유도배수공법을 제시하였다. 유도배수공법은 유도배수판, 철망, 고정핀, 광물질 혼입 모르타르로 구성된다. 시공성 향상을 위하여 유도배수판 및 철망은 공압타카와 고정핀를 사용하여 콘크리트 표면에 부착하였다. 고로슬래그미분말을 30% 혼입한 모르타르는 뿜어 붙임 모르타르 장비를 사용하여 유도배수판 및 철망 표면에 타설하였다. 유도배수공법의 현장 시공성 및 성능 검증을 위하여 재래식 콘크리트라이닝 터널과 콘크리트 옹벽에서 시험시공을 수행하였다. 시험시공 완료 3년 후 유도배수공법은 성능저하의 문제점이 없는 것으로 판단되었다. 재령 14일과 3년에 뿜어 붙임 모르타르의 부착력 실험을 수행하였다. 유도배수판 표면에 철망을 적용한 경우 뿜어 붙인 모르타르의 부착력은 재령 14일에 1.04 MPa, 재령 3년에 1.46 MPa로 측정되었다. 철망을 적용하지 않은 경우의 부착력은 재령 14일에 1.13 MPa로 측정되었지만, 재령 3년에는 0.89 MPa로 기준 부착력 1 MPa보다 낮게 측정되었다.

• Journal of Pharmaceutical Investigation
• /
• 제32권3호
• /
• pp.215-221
• /
• 2002

Cephradine is a first generation cephalosporin and has broad spectrum antibacterial activity against gram-positive and gram-negative microorganisms, through inhibition of bacterial cell wall synthesis. Cephradine is useful for treatment of infections of the urinary and respiratory tract, skin and soft tissues. The purpose of the present study was to evaluate the bioequivalence of two cephradine capsules, Cefradine Yuhan (YuHan Corporation) and Broadcef (Ilsung Pharmaceuticals Co. Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The cephradine release from the two cephradine capsules in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty normal male volunteers, $23.10{\pm}2.90$ years in age and $67.69{\pm}8.04\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one capsule containing 500 mg as cephradine was orally administered, blood was taken at predetermined time intervals and the concentrations of cephradine in serum were determined using HPLC method with UV detector. The dissolution profiles of two cephradine capsules were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AVC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AVC_t\;and\;C_{max}$ and untransformed $T_{max}$. The results showed that the differences in $AVC_t,\;C_{max}\;and\;T_{max}$ between two capsules based on the Cefradine Yuhan were -2.87%, -0.96% and -4.85%, respectively. There were no sequence effects between two capsules in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of 1og(0.8) to log(1.25) $(e.g.,\;log(0.93){\sim}log(1.02)\;and\;log(0.88){\sim}log(1.13)\;for \;AVC_t\;and\;C_{max},\;respectively)$. The 90% confidence interval using untransformed data was within ${\pm}20%$ $(e.g., \;-17.54{\sim}7.78\;for\;T_{max})$. All parameters met the criteria of KFDA guideline for bioequivalence, indicating that Broadcef capsule is bioequivalent to Cefradine Yuhan capsule.

• 한국콘텐츠학회논문지
• /
• 제15권8호
• /
• pp.336-344
• /
• 2015

본 연구는 우리나라 지역사회 거주노인을 대상으로 대사증후군 및 개별 위험요인과 우울간의 관련성을 확인하기 위해 시도되었다. 연구자료는 제5기 국민건강영양조사 원시자료를 이용하였으며, 연구 대상자는 65세 이상 노인 중 검진조사 내용이 부실한 자료를 제외한 3,755명이었다. 대사증후군 및 개별 위험인자와 우울의 연관성을 확인하기 위하여 다중로지스틱회귀분석을 실시하였다. 연구결과 재가노인의 대사증후군은 우울과 유의한 관계가 없었으나(95%Confidence Interval [CI]=0.980-1.569), 대사증후군 위험인자 중 낮은 고밀도지단백 콜레스테롤혈증(high-density lipoprotein cholesterol, HDL-C) 과 우울은 유의한 관계가 있었다(Odds raio[OR]=1.26, 95%Confidence Interval [CI]=1.002-1.584). 여성노인의 경우 대사증후군(OR=1.36, 95%CI=1.029-1.792), 혈당상승(OR=1.41, 95%CI=1.070-1.851), 저HDL-콜레스테롤혈증(OR=1.21, 95%CI=1.078-1.746)과 우울은 유의한 관계가 있었다. 반면, 남성노인의 경우 대사증후군 및 개별 위험인자와 우울과는 유의한 관계가 없는 것으로 나타났다. 결론적으로 우리나라 여성노인의 경우 대사증후군과 우울은 유의한 양의 관계가 있었으나, 남성노인에서는 유의한 관계가 없었다.

• 한국산학기술학회논문지
• /
• 제18권7호
• /
• pp.483-489
• /
• 2017

본 연구의 목적은 직물의 발수도 판정 (KS K 0590) 시 이미징 기반의 판별을 통해서 측정 신뢰도를 향상하는 것으로 한다. 이를 수행하기 위하여 가장 먼저 우리는 Java 기반의 이미지 처리 프로그램을 통해서 발수도 판정 표준표를 정량화하였다. 이때 모든 이미지의 처리과정은 미 국립보건원(NIH)에서 개발한 오픈 소프트웨어인 Image J를 사용하였다. 발수도 판정 표준표(standard spray test rating)에 대한 이미지 처리과정은 면적 측정 기법을 통해서 수행하였으며, 이를 통해서 정량화한 결과, 습윤 면적비 수치를 기반으로 하는 손쉬운 판정기준을 확보 할 수 있었다. 또한 실제 직물에 있어서 이미징 기반의 발수도 판정을 도입하기 위한 최적화 처리기법을 도출하기 위하여 형광물질을 사용하였다. 형광 이미지를 도입하여 문턱값 (Threshold) 조절과 2치이미지 (Binary Image) 변환 등의 과정을 통해서 발수도 판정을 위한 데이터 처리과정을 진행하였다. 본 연구의 결과물은 향후 직물의 발수도 판정 (KS K 0590)에 있어서 기존의 정성적인 분석법에서 탈피하여 정량적인 측정 신뢰도 향상을 위한 방안으로 적용할 수 있으리라 판단된다.

• Journal of Pharmaceutical Investigation
• /
• 제32권2호
• /
• pp.135-140
• /
• 2002

Cefadroxil is a semi-synthetic cephalosporin active against many Gram-positive and Gram-negative bacteria. The drug has been used for the treatment of the urinary and respiratory tract infections when caused by susceptible strains of the designated microorganism. The purpose of the present study was to evaluate the bioequivalence of two cefadroxil capsules, Duricef (Bo Ryung Pharmaceutical Co. Ltd.) and Hanacef (Korean Pharmaceutical Co. Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The cefadroxil release from the two cefadroxil capsules in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty four normal male volunteers, $21.58{\pm}2.43$ years in age and $70.74{\pm}10.29$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one capsule containing 500 mg as cefadroxil was orally administered, blood was taken at predetermined time intervals and the concentrations of cefadroxil in serum were determined using HPLC with UV detector. The dissolution profiles of two cefadroxil capsules were very similar at all dissolution media. The pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t\;and\;C_{max}$ and untransformed $T_{max}$. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between two capsules based on the Duricef were 0.05%, -5.29% and 4.53%. There were no sequence effects between two capsules in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) $(e.g.,\;log(0.95){\sim}log(1.05)\;and\;log(0.87){\sim}log(1.02)$ for $AUC_t\;and\;C_{max}$, respectively). The 90% confidence interval using untransformed data was within ${pm}20%$ $(e.g.,\;-6.75{\sim}15.74\;for\;T_{max})$. All parameters met the criteria of KFDA guideline for bioequivalence, indicating that Hanacef capsule is bioequivalent to Duricef capsule.

• Journal of Pharmaceutical Investigation
• /
• 제41권5호
• /
• pp.317-322
• /
• 2011

Sertraline HCl, (1S-cis)-4-(3, 4-dichloro-phenyl)-1, 2, 3, 4-tetrahydro-N-methyl-l-naphthalenamine hydrochloride, is a potent and selective serotonin reuptake inhibitor which is used in the treatment of depression and obsessivecompulsive disorders. The purpose of the present study was to evaluate the bioequivalence of two sertraline HCl tablets, Traline tablet (Myungin Pharm. Co. Ltd.) and Zoloft$^{(R)}$ tablet (Pfizer Inc.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The in vitro release of sertraline from the two sertraline HCl formulations was tested using KP VIII Apparatus II method with various dissolution media. Twenty four healthy Korean male volunteers, $23.50{\pm}1.74$ years in age and $64.09{\pm}7.10\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ crossover study was employed. After a single tablet containing 50 mg as sertraline HCl was orally administered, blood samples were taken at predetermined time intervals and the concentrations of sertraline in serum were determined using an online columnswitching HPLC method with UV/Vis detection. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated, and computer programs (Equiv Test and K-BE Test) were utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and un-transformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, Zoloft$^{(R)}$ tablet, were 0.04, 3.26 and -1.29% for $AUC_t$, $C_{max}$, and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log0.8 to log1.25. Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Traline tablet was bioequivalent to Zoloft$^{(R)}$ tablet.

• 대한환경공학회지
• /
• 제35권11호
• /
• pp.781-784
• /
• 2013

하수슬러지의 해양투기가 금지됨에 따라 하수슬러지의 적정처리에 대한 요구가 커지고 있다. 따라서 본 연구에서는 하수슬러지와 폐유리를 이용하여 경량벽돌을 제조하고자 하였다. 건축자재인 벽돌은 통상 $1,200^{\circ}C$ 이상의 고온에서 제조되기 때문에 벽돌 제조시 다량의 에너지가 소비된다. 본 연구에서는 하수슬러지와 폐유리를 이용하여 경량벽돌 제조시 $CO_2$ 배출량을 줄이기 위해 $800^{\circ}C$ 이하의 낮은 온도에서 지오폴리머 기술을 이용하여 벽돌을 제조하였다. 경량벽돌 제조시 소성온도, 하수슬러지와 폐유리 및 물유리와 물의 혼합비 등이 주요 영향 인자이며, 이들의 변화에 따른 경량벽돌의 특성을 평가하였다. 본 연구결과에 따르면 경량벽돌의 최적 제조조건은 소성온도 $750^{\circ}C$, 물유리/물 혼합비 1.5, 하수슬러지/폐유리 비 10 : 90 wt%였다. 이때 제조한 경량벽돌의 압축강도 5.1 MPa, 비중 0.46으로 발포세라믹 경량벽돌 기준을 만족시키는 것으로 나타났다.